natgillin/translations-raw huggingface dataset:
Solid pharmaceutical formulation according to claim 13 for use in a method of prophylaxis or method of treatment for diseases selected from the group comprising HCMV infections in a subject, particularly HCMV infections in a subject having AIDS, HCMV-pneumonitis, HCMV-encephalitis, as well as gastrointestinal and systemic HCMV infection, HCMV infections in newborn and children, acute HCMV infection of pregnant women, HCMV infection in immuno-suppressed cancer patients, HCMV-positive cancer patients to address HCMV-mediated tumor progression. 
Kruta farmaceutska formulacija prema zahtjevu 13, za uporabu u postupku profilakse ili postupku liječenja za bolesti odabrane iz skupine koja sadrži HCM zaraze kod subjekta, posebno HCMV zaraze kod subjekta koji ima AIDS, HCMV-pneumonitis, HCMV -encefalitis, kao i gastrointestinalne i sistemske HCMV zaraze, HCMV zaraze kod novorođenčadi i djece, akutne HCMV zaraze kod trudnih žena, HCMV zaraze u pacijentima potisnutog imunološkog sustava s rakom, HCMY -pozitivne pacijente s rakom kako bi se adresirao HCMY -posredovani razvoj tumora.
These compounds are used for wood preservation for almost 20 years. 
Ti spojevi se upotrebljavaju za konzerviranje drva već skoro 20 godina.
The anti-CD 154 antibody or the CD 154-binding fragment thereof according to claim 3, comprising heavy and light chain sequences of SEQ ID NO: 13 of Figure 7 and SEQ ID NO: 15 of Figure 7, respectively. 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s patentnim zahtjevom 3, naznačeno time što sadrži sljedove teškog i lakog lanca sa SEQ ID NO: 13 na Slici 7 odnosno SEQ ID NO: 15 na Slici 7.
The solid form of claim 1, which exhibits a mass increase of less than approximately 0.5% when subjected to an increase in relative humidity from approximately 0% to approximately 95%. relative humidity. The solid form of claim 1, which is substantially nonhygroscopic. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što čvrsti oblik pokazuje povećanje mase manje od otprilike 0,5% kada se podvrgne povećanju relativne vlažnosti od otprilike 0% do otprilike 95% relativne vlažnosti.
The method of claim 1, wherein the dosing regimen results in a plasma buprenorphine concentration after administration of the third transdermal patch of about 800 pg/ml. 
Korištenje iz zahtjeva 6, naznačeno time da režim doziranja dovodi do profila buprenorfina u plazmi gdje srednja koncentracija buprenorfina u plazmi nakon davanja narednog oblika doziranja iznosi približno 800 pg/ml.
a disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crosslinked polyvinylpyrrolidone and mixtures thereof. 
(c) razgrađivač odabran iz skupine kroskarameloza natrija, natrij škrob glikolata, međupovezanog polivinilpirolidona i njihovih smjesa.
a heavy chain variable region comprising SEQ ID NO:32 or a heavy chain variable region comprising SEQ ID NO:32 which comprises the substitution M34I, and a light chain variable region comprising SEQ ID NO:76. 
varijabilno područje jakog lanca odabrano iz skupine koju čine SEQ ID NO:32 i SEQ ID NO:40, i varijabilno područje KV1 slabog lanca od SEQ ID NO:76.
wherein each RP is independently a ring substituent; or wherein Ar1-Ar2- is independently a group of the following formula: 
[image] gdje RP je neovisno supstituent u prstenu; ili gdje Ar1-Ar2-je neovisno skupina sljedeće formule:
A medicament comprising an effective amount of at least one compound as claimed in any of claims 1 to 55 and/or a pharmacologically acceptable salt thereof, pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients. 
Medikament, naznačen time što sadrži djelotvornu količinu najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 55, i/ili njegove farmakološki prihvatljive soli, fatmaceutski prihvatljive pomoćne tvari i podloge, te, gdje je to prikladno, dodatne aditive i/ili druge aktivne sastojke.
coupling the 2-3 eptifibatide fragment and the 4-6 eptifibatide fragment through attachment of the Gly residue of the 2-3 eptifibatide fragment to the Asp residue of the 4-6 eptifibatide fragment, thereby forming a 2-6 eptifibatide fragment of the formula: 
P:-Asp(O-P>2)-Trp-Pro-OH; kopuliranje fragmenta 2-3 eptifibatida i fragmenta 4-6 eptifibatida putem vezivanja Gly ostatka fragmenta 2-3 eptifibatida na Asp ostatak fragmenta 4-6 eptifibatida, da na taj način nastane fragment 2-6 eptifibatida formule:
1 shows an extraction capsule known from EP-A-512470, 
Slika 1 prikazuje čahuru za istakanje koja je poznata iz EP-A-512470,
Aspect 7. Process according to anyone of aspects 1 to 6, comprising, after step (ii) and the optional laminating and folding steps, a step of cooling the dough. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da nakon koraka (ii) i dodatnih postupaka valjanja i preklapanja, obuhvaća korak hlađenja tijesta.
To avoid disturbance of an actual drilling operation by the method according to the invention, the torque imposed by the drive system is varied over the time period to provide a limited variation of the top end drive speed of the drill string, for example a variation less than 10-15% of a set rotational top end drive speed of the drill string. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se navedeni okretni moment kojeg nameće navedeni pogonski sustav (15) mijenja tijekom navedenog vremenskog perioda, kako bi se osiguralo ograničenu promjenu navedene vršne brzine vrtnje pogona navedene bušaće šipke (12).
A solid dosage form comprising the crystalline polymorph of embodiment 8. The solid dosage form of embodiment 9, wherein the polymorph of Formula I is present from about 75% to about 99.99% of the total weight. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u od 75% do 99,99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
The composition of claim 7 further comprising at least one additional compound having therapeutic benefits for HCV wherein the compound is selected from the group consisting of interferons, cyclosporins, interleukins, HCV metalloprotease inhibitors, HCV serine protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, HCV NS4B protein inhibitors, HCV entry inhibitors, HCV assembly inhibitors, HCV egress inhibitors, HCV NS5A protein inhibitors, HCV NS5B protein inhibitors, and HCV replicon inhibitors. 
Smjesa prema zahtjevu 7, naznačena time što dalje sadrži barem jedan dodatni spoj s terapijskim učinkom na virus hepatitisa C (HCV) pri čemu se taj spoj izabire iz skupine koja obuhvaća interferone, ciklosporine, interleukine, inhibitore metaloproteaze HCV-a, inhibitore serin proteaze HCV-a, inhibitore polimeraze HCV-a, inhibitore helikaze HCY-a, inhibitore proteina NS4B HCV-a, inhibitore ulaska HCV-a, inhibitore nakupljanja HCV-a, inhibitore izlaska HCV-a, inhibitore proteina NS5A HCV-a, inhibitore proteina NSS5B HCV-a i inhibitore replikacije HCV-a.
Idebenone according to any of claims 1 to 5, wherein the idebenone is administered by an oral wafer, a fast disintegrating oral film form product for the delivery of pharmaceutical ingredients or via orally disintegrating tablet (ODT). 
Ibedenon za upotrebu prema bilo kojem patentnom zahtjevu od 1. do 5., naznačen time da se ibedenon primjenjuje u kapsuli od hostije, proizvodu u obliku filma koji se brzo rastapa u ustima i koji sadržava farmaceutske sastojke ili u obliku tablete koja se rastapa u ustima.
The particulate polylactic acid according to claim 1 wherein the polylactic acid comprises a chain extender, selected from the group consisting of polyepoxides and diepoxides, diisocyantates, oxazines and oxazolines, cyclic dianhydrides, organic peroxides and one or more combinations thereof. 
Partikulirana polimliječna kiselina u skladu s bilo kojim od ili više prethodnih patentnih zahtjeva, naznačena time što polimliječna kiselina sadrži produljivač lanca, koji se po mogućnosti bira iz skupine koju čine poliepoksidi i diepoksidi, diizocijanati, oksazini i oksazolini, prstenasti dianhidridi, organski peroksidi 1 jedna ili više njihovih kombinacija.
The coating material as recited in claim 1, further comprising an inorganic filler. The coating material as recited in claim 1, wherein the hydroxy-functional binder component comprises the aqueous polymer dispersion in an amount of 10 to 40 wt % based on a total weight of the hydroxy-functional binder component. 
Obložni materijal prema zahtjevu 1 ili 2, naznačen time, da vezivna komponenta sadrži polimernu disperziju u udjelima od 10 do 40 masenih %, poželjno od 15 do 35 masenih %, posebno poželjno od 20 do 30 masenih %, na bazi ukupne mase vezivne komponente.
The compound or salt of claim 12 wherein said disease is a skin disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 20, pri čemu je bolest mijeloproliferativni poremećaj.
Production of Monoclonal Antibodies of the Invention 
Datum objave europske prijave patenta:
Rf is chosen from the group consisting of hydrogen, hydroxyl group, halogen or forms a carbonyl group with the carbon atom to which it is linked; 
R' se bira iz skupine koju čine vodik, hidroksilna skupina, halogen, ili tvori karbonilnu skupinu s atomom ugljika na kojeg je vezan;
wherein said heavy chain comprises the amino acid sequences of SEQ ID NO: 46 and the allotypic modification is a replacement of K93R, D235E and L237M within the amino acid sequence of SEQ ID NO: 46. 
pri čemu navedeni teški lanac sadrži aminokiselinske sekvence sukladno SEQ ID NO: 46 i alotipska modifikacija je zamjena K93R, D235E i L237M unutar aminokiselinske sekvence prema SEQ ID NO: 46.
G is represented by the following formula (IV): 
G je predstavljeno sljedećom formulom (IV): gdje
The heat conducting member preferably employed in practicing this invention is typically a metallic foil, such as aluminum foil, varying in thickness from less than about 0.01 mm to about 0.1 mm, or more. 
Član za provođenje topline je tipično metalna folija, kao što je aluminijska folija, koja varira po debljini od manje od oko 0.01 mm do oko 0.1 mm, ili više.
The isolation system of claim 1, wherein said metal fastener further comprises a metal shaft threaded to receive a nut on at least one of said opposing ends. 
Izolacijski sustav prema zahtjevu 1, naznačen time, da spomenuti metalni pričvršćivač (18) nadalje obuhvaća metalni vijak s navojem za prihvat matice na najmanje jednom od spomenutih suprotnih krajeva.
Turn off the heating in the drying chamber and allow the lozenges to cool for 24 hours. 
Isključiti zagrijavanje u komori za sušenje i ostaviti tablete da se suše 24 sata.
stitching said folded gusset (14') directly onto said mattress panel (1') along a first seam (15) inwardly recessed from the edge of the mattress panel, in correspondence with said fold dividing the gusset into two parts; 
šivanje presavinutog ušitka (14’) izravno na oblogu madraca (1’) duž prvog šava (15) okrenutog prema unutra od ruba obloge madraca, što odgovara mjestu gdje mjesto presavijanja dijeli ušitak na dva dijela;
The JNK inhibitor sequence of any of claims 1 to 4, wherein the JNK inhibitor sequence alters a JNK effect when the peptide is present in a JNK expressing cell. A chimeric peptide consisting of a first domain and a second domain linked by a covalent bond, the first domain comprising a trafficking sequence, and the second domain consisting of a JNK inhibitor sequence according to any one of claims 1-5, wherein the first domain is linked to the C-terminal end of the second domain. 
Kimerni peptid koji sadrži prvu domenu, drugu domenu i proizvoljno vezujuću sekvencu, te prva domena sadrži transportnu sekvencu i druga domena sadrži JNK inhibicijsku sekvencu, naznačen time da prva domena sadrži sve-D retro-inverzo sekvence amino kiseline u skladu sa SEQ ID NO:6 te time da druga domena sadrži sve-D retro-inverzo sekvence amino kiseline u skladu sa SEQ ID NO:2, pri čemu je prva domena vezana na C-terminalni kraj druge domene bilo izravno ili pomoću navedene vezujuće sekvence koja sadrži 1 do 10 amino kiselina.
a mutated Tsp gene, wherein the mutated Tsp gene encodes a Tsp protein having 50% or less of the protease activity of a wild-type non-mutated Tsp or is a knockout mutated Tsp gene; and 
omutirani Tsp gen, pri čemu mutirani Tsp gen kodira Tsp protein koji ima 50% ili manje aktivnosti proteaze od divljeg tipa ne-mutiranog Tsp ili je,knockout" mutirani Tsp gen; i b.
The filter cake is then dried in an oven 60° C. overnight. 
Kolač od filtriranja je zatim zagrijavan u peći pri 60 X preko noći.
It includes, but is not limited to, chronic plaque psoriasis, guttate psoriasis, erythrodermic psoriasis, pustular psoriasis, inverse psoriasis (also known as flexural psoriasis), nail psoriasis, psoriatic arthritis. 
Rafinirani ekstrakt namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je psorijaza kronična pločasta psorijaza, kapljičasta psorijaza, eritrodermna psorijaza, pustozna psorijaza, inverzna psorijaza, psorijaza noktiju i/ili psorijatični artritis.
Like other opioid agonists, buprenorphine produces dose-related analgesia. 
Kao i ostali opioidni agonisti, buprenorfin dovodi do analgezije koja je ovisna o dozi.
The solid formulation according to any one of claims 2 to 4, characterized in that the disintegrant/carrier is selected from the group consisting of lactose, starch, cellulose, microcrystalline cellulose and methylcellulose, preferably characterized in that the carriers are starch and lactose. 
Kruti pripravak prema zahtjevu 2 ili 3, naznačen time, da je dezmtegrant/nosač odabran iz skupine koju čine laktoza, škrob, celuloza, mikrokristalna celuloza i metilceluloza, a poželjno je naznačen time, da nosači su škrob 1 laktoza.
In FIG. 1, 1 denotes a sampler according to the invention. It comprises a plunger 2 which is arranged in a cylinder 4 . 
Na slici 1 je brojem 1 označena naprava za uzimanje uzorka, koja naprava je u skladu s ovim izumom. Ona obuhvaća klipnjaču 2 koja se nalazi u cilindru 4.
The present invention is related to the use of Glepp-1 inhibitors for the manufacture of a medicament for the treatment of autoimmune and/or inflammatory disorders. 
Upotreba Glepp-1 inhibitora za proizvodnju lijeka za liječenje autoimunih i/ili upalnih poremećaja naznačena time da Glepp-I inhibitor je karboksilna kiselina prema formuli (I):
the block comprising a 1,4-cis structure has a glass transition temperature Tg lower than or equal to −100° C., a melting point Tm lower than or equal to −2° C., and a crystallization temperature Tc lower than or equal to −25° C.; and 
– blok koji ima 1,4-cis strukturu ima temperaturu stakljenja (Tg) ispod ili jednaku –100 °C, talište (Tm) ispod ili jednako –2 °C i temperaturu kristalizacije (Tc) ispod ili jednaku –25 °C;
The waterproof liner according to claims 19 or 21, characterised in that the watertight flexible flaps (26) of adjoining panels (14) are connected to each other in a slack manner. 
Vodonepropusna obloga u skladu s patentnim zahtjevima 19 ili 21, naznačena time, da su vodonepropusni savitljivi preklopi (26) susjednih ploča (14) labavo povezani jedan s drugim.
In addition, IL-18BP inhibits induction of IFN-Y in mice injected with LPS. 
Dodatno, IL-18BP inhibira indukciju IFN-y u miševa kojima je bio injektiran LPS.
In fact, the hydraulic damper on its own would be too weak to sustain the recoil impulse. 
U stvari, hidraulički prigušivač je sam po sebi suviše slab da izdrži impuls trzanja.
The melter assembly of claim 12 in which the submerged combustion burners are arranged at a distance between adjacent burners of about 250-1250mm. 
gdje se plamenici za uronjeno izgaranje (21) nalaze na udaljenosti između susjednih plamenika od 250 do 1250 mm, pogodno 500 do 900 mm, po mogućnosti 600 do 800, još poželjnije 650 do 750 mm.
[4-(Thiazol-2-ylcarbamoyl)-phenyl]-carbamic acid tert-butyl ester was deprotected prior to use by dissolution in dichoromethane/trifluoroacetic acid (1:1) for 10 min., followed by evaporation of the solvent. 
Terc butil esteru [4-(tiazol-2-ilkarbomoil)-fenil]-karbamatne kiseline se ukloni zaštita prije upotrebe sa otapanjem u diklorometan/trifluoroctenoj kiselini (1:1) kroz 10 minuta, potom se otapalo upari.
A method according to claim 9 or 10, wherein the enzyme-loaded particles of fibre fraction is fed into and moved through an elongated liquefaction reactor, filled with a fluid of liquefied fibre fraction. 
Postupak sukladno zahtjevu 9 ili 10, pri čemu se čestice pune enzima u vlaknastom dijelu unose i pomiču kroz dugački reaktor za rastapanje, napunjen tekućim vlaknastim dijelovima.
The process of claim 6, wherein the solvent is selected from the group consisting of water, isopropanol, methanol, ethanol, and an appropriate mixture of any two or more of the aforementioned solvents. 
Postupak prema zahtjevu 22, naznačen time da je otapalo alkohol. Postupak prema zahtjevu 23, naznačen time da je alkohol odabran iz skupine koja se sastoji od metanola, etanola i izopropanola.
The method of claim 10, wherein the plurality of passengers comprises at least forty passengers, the method comprising vertically repositioning the cabin with respect to the deck. 
Metoda iz zahtjeva 9, naznačeno time da pluralitet putnika (108) sačinjava barem četrdeset putnika.
contacting (R,S)-THP (I) with the optically active arylpropionic acid, optionally in admixture with a further optically active acid or with an inorganic acid, in a suitable solvent system, 
Postupak razdvajanja (R,S)-Tetrahidropapaverina (THP) (1) pomoću optički aktivne arilpropionske kiseline, po izboru u smjesi s dodatnom optički aktivnom kiselinom ili anorganskom kiselinom, u odgovarajućem sustavu otapala.
The assembly according to claim 7, wherein said elongated flexible body includes a first tube at said first end having a first diameter and a second tube at said second end having a second diameter smaller than said first diameter and including a tapered portion connecting said first tube to said second tube. 
Sklop u skladu s patentnim zahtjevom 1, naznačen time što navedeno izduženo savitljivo tijelo obuhvaća prvu cijev na navedenom prvom kraju (16) koja ima prvi promjer 1 drugu cijev na navedenom drugom kraju (12) koja ima drugi promjer manji od navedenog prvog promjera i uključuje konusni dio (18) koji povezuje prvu cijev s navedenom drugom cijevi.
All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety. A liposome for topical administration consisting of dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, and cationic lipid, wherein the phosphatidylcholine has one or more features selected from (i) to (iii) below: 
Liposom, naznačen time, da se upotrebljava pomoću topikalne primjene u postupku medicinskog liječenja, te koji se sastoji od dioleilfosfatidiletanolamina (DOPE), fosfatidilkolina 1 kationskog lipida, pri čemu fosfatidilkolin obuhvaća najmanje jedan lanac nezasićene masne kiseline koji sadrži dvostruku vezu ugljik-ugljik, i pritom kationski lipid je O,O'-ditetradekanoil-N-(a-trimetilamonioacetil)dietanolaminklorid (DC-6-14).
The antibody or antigen-binding fragment of any one of claims 1-5, wherein the patient has renal cancer. 
Protutijelo ili njegov ulomak koji veže antigen u skladu s patentnim zahtjevom 12, naznačeno time što pacijent ima fibroznu bolest, rak, ili imunološki posredovanu bolest.
Preferred alkyl groups have 1 to 12 carbon atoms in the chain. 
Poželjne alkilne skupine imaju 1 do 12 ugljikovih atoma u lancu.
Embodiment 9 A radiation curable gel nail coating composition according to any one of embodiments 1 to 8, wherein the plasticizer is selected from sucrose acetate isobutyrate, ethyl tosylamide, and camphor, or a mixture thereof. 
Pripravak u vidu gel-laka za nokte za čije sušenje se korisiti zračenje prema patentnom zahtjevu 6, naznačen time, što je plastifikator izabran iz grupe koju čine acetat izobutirat saharoza, etil tozilamid, kamfor i njihove smjese.
a rotatably mounted gear wheel having a circular arrangement of ratchet teeth defining a root circle; 
zupčasti kotač montiran s mogućnošću rotiranja (130) koji ima kružno postavljen zaporni zubac (132) koji određuju osnovni krug;
total number of TEAE's (n) 
(87) Broj međunarodne objave:
The method of claim 4, wherein the aminooxy compound is chosen from compounds of Formula III: wherein Y is the second reactive group, n is chosen from integers ranging from 1 to 10, and P is chosen from amino protecting groups. 
Postupak prema patentnom zahtjevu 2, naznačen time što je aminooksi spoj odabran od spojeva s Formulom III: pri čemu Y je druga reaktivna skupina, n je odabran od cijelih brojeva u rasponu od 1 do 10, i P je odabran od amino zaštitnih skupina.
The antibody according to any one of embodiments 23-34, wherein the antibody comprises a substitution an Fc region. 
Protutijelo sukladno patentnom zahtjevu 6, naznačeno time, da protutijelo sadrži supstituciju u Fc Tegiji.
Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and losenges, as well as liquid syrups, suspensions and elixirs. 
Dozirni oblici uključuju čvrste oblike kao što su tablete, prašak, kapsule, supozitoriji, vrećice, dražeje i pastile, kao i tekući sirupi, suspenzije i eliksiri.
Method according to one of the claims 15-17, wherein after sampling a container is provided and the contents of the sampling tube is transferred to said container which is subsequently closed and shipped. 
Postupak u skladu s jednim od patentnih zahtjeva 15 - 17, kod kojega se predviđa spremnik u koji se, nakon uzimanja uzorka u cijev za uzimanje uzorka, ova cijev za uzimanje uzorka prenese u navedeni spremnik koji se nakon toga zatvara i otprema.
The organic phase was dried over MgSO4, filtered and evaporated. 
Organska faza se osuši preko MgSO, filtrira i upari.
A compound according to claim 1, which is an acid addition salt of (E)-N-hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide with any acid selected from the group consisting of methanesulphonic acid, ethanesulfonic acid, toluenesulphonic acid, benzenesulfonic add and naphthalene-2-sulfonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (E)-N-hidroksi-3-[1-(5-piridin-2-iltiofen-2-sulfonil)-1Z7-pirol-3-iljakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine metansulfonska kiselina, etansulfonska kiselina, toluensulfonska kiselina, benzensulfonska kiselina i naftalen-2-sulfonska kiselina, ili njegov hidrat.
The antibody, the conjugate, or the pharmaceutical composition of claim 21 wherein the cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. The antibody, the conjugate, or the pharmaceutical composition of claims 21 or 22 wherein said CLD 18A2 is expressed on the surface of said cells. 
Protutijelo, konjugat ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 10 pri čemu je bolest ili poremećaj bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz grupe koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma gušterače, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave i vrata, karcinoma žučnog mjehura i njihovih metastaza.
the concentration of mature type I elastase protein in said pharmaceutical composition is 0.001-50 mg/ml and the composition further comprises 8% dextran-18 and optionally 0.1% polysorbate-80; or 
(iii) koncentracija zrelog tipa I protein elastaze u spomenutom farmaceutskom sastavu je 0.001-50 mg/ml i sastav dalje sadrži 8% dekstrana-18 i opcionalno 0,1% polisorbat-80; ili
Alternative formulations have been developed, in which the particle size of active is reduced by milling. 
Razvijeni su alternativni pripravci, u kojima se veličina čestica smanjuje mljevenjem.